Evidence map›Paper›PMID 41920765›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells.

William-Ray Vista, Vaishali Malik, Mary Chase Sheehan, Jaad Ismail, Hocine R Hocine, Undrakh Ganbaatar, Kyohei Misawa, Jesus Guzman Valle, Srijita Banerjee, Stephen B Solomon and 2 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

William-Ray VistaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5254-2336
Vaishali MalikDepartment of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts.ORCID 0009-0007-8105-2046
Mary Chase SheehanDepartment of Mechanical and Industrial Engineering, University of Massachusetts, Amherst, Massachusetts.ORCID 0000-0002-0767-7378
Jaad IsmailDepartment of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts.ORCID 0009-0007-5267-0531
Hocine R HocineThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1144-9818
Undrakh GanbaatarThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0005-7849-5108
Kyohei MisawaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3835-5889
Jesus Guzman ValleThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5198-2038
Srijita BanerjeeThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0009-8432-6019
Stephen B SolomonInterventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5108-1021
Prasad S Adusumilli *Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1699-2046
Govindarajan Srimathveeravalli *Department of Mechanical and Industrial Engineering, University of Massachusetts, Amherst, Massachusetts.ORCID 0000-0001-8885-3830

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7M
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesotheliomaR01CA235667 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S. · 2019 to 2024
$3.6M
Tuning KITv CAR T cells for the solid tumor environmentR01CA292664 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Prasad S. Adusumilli · 2024 to 2026
$3.2M
CD28-KITv CAR T cells with PD-1 dominant negative receptorUG3CA290241 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S. · 2024 to 2025
$3.1M
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumorsR01CA236615 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., SOLOMON, STEPHEN BARNETT · 2018 to 2022
$2.0M
Intrasurgical tissue engineering of autologous grafts using irreversible electroporation for bladder reconstructionR01DK129990 · NIDDK · UNIVERSITY OF MASSACHUSETTS AMHERST · PI SRIMATHVEERAVALLI, GOVINDARAJAN · 2021 to 2024
$1.4M
Adolfo F. Sardina Charitable FoundationBaker Street FoundationBatishwa FellowshipCenter for Experimental Therapeutics of Memorial Sloan Kettering Cancer CenterDerfner Foundation (The Derfner Foundation)Esophageal Cancer Education FundInstitute for Applied Life Sciences at the University of Massachusetts at AmherstJoanne and John Dallepezze Foundation (The Joanne & John Dallepezze Foundation)Memorial Sloan Kettering Technology Development FundMr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer ResearchNational Institutes of Health (NIH) R01CA235667National Institutes of Health (NIH) R01CA236615National Institutes of Health (NIH) R01CA292664National Institutes of Health (NIH) R01DK129990National Institutes of Health (NIH) T32CA009501National Institutes of Health (NIH) UG3CA290241NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA235667NCI NIH HHS R01 CA236615NCI NIH HHS R01 CA292664NCI NIH HHS T32 CA009501NCI NIH HHS UG3 CA290241NIDDK NIH HHS R01 DK129990NovocureU.S. Department of Defense (DOD) CA200437U.S. Department of Defense (DOD) CDMRP PRCRP Award CA170630 and CA190888
6 · The paper itself

Abstract

purposeOne recurring challenge in cell therapy for solid tumors is poor tumor infiltration of adoptively transferred T cells. We previously showed that a subablative dose of tumor-targeted radiation generates a chemokine gradient that promotes infiltration, proliferation, and a memory phenotype of chimeric antigen receptor (CAR) T cells in solid tumors. However, radiation is cytotoxic to infiltrating CAR T cells, limiting its repeated use. EXPERIMENTAL

designWe hypothesized that irreversible electroporation could generate a chemokine gradient that promotes CAR T-cell infiltration into solid tumors and that selective irreversible electroporation (sIRE) tuned for selective cancer cell lysis (thus sparing infiltrating CAR T cells) can be used in a repeated fashion. Using experimental screening and simulation models, we optimized sIRE parameters to kill cancer cells while sparing T cells.

resultsUsing 3D tumor mimics and mouse models of malignant pleural mesothelioma, we confirmed the therapeutic benefit of repeated sIRE. Chemokine secretion by cancer cells injured by sIRE promoted migration and tumor infiltration of systemically administered CAR T cells and facilitated sustained immunity in a tumor-rechallenge model.

conclusionsBy leveraging a dual-purpose translational strategy-through direct cancer cell-targeted cytotoxicity and augmented CAR T-cell infiltration-sIRE can reduce cancer burden while preserving and enhancing CAR T-cell function.

Indexed as

Cytotoxicity, ImmunologicElectroporationImmunotherapy, AdoptiveLung NeoplasmsMesotheliomaNeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansIrreversible Electroporation TherapyLymphocytes, Tumor-InfiltratingMesothelioma, MalignantReceptors, Chimeric Antigen

Identifiers

PMID41920765
PMCPMC13154003

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.